 ATLANTA--BUSINESS WIRE--- VIRI Biotech--Virios Therapeutics, Inc. Nasdaq: VIRI, a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today that Chairman and CEO, Greg Duncan, highlighted the Companys novel combination antiviral development approach, its ongoing Phase 2b trial Fibromyalgia trial and plans for expanded pipeline programs in irritable bowel syndrome IBS and fatigue related disorders during a video interview w 